Alentis Therapeutics is a clinical-stage biotechnology company pioneering first-in-class antibody-drug conjugates (ADCs) and antibodies targeting Claudin-1. They are focused on developing innovative treatments for CLDN1+ tumors, cancer, and fibrotic diseases, including advanced liver diseases.
- Category
- Drug Discovery & Development
- Stage
- Series D+
- Employees
- 67
- HQ
- Allschwil, Switzerland
- Founded
- 2019
- Funding
- $366M